Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?

Autor: Giovene GL; Private Practitioner, Perugia, Italy - gianluigi.giovene@gmail.com., Giacomelli L; Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy.
Jazyk: angličtina
Zdroj: Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia [G Ital Dermatol Venereol] 2018 Dec; Vol. 153 (6), pp. 872-876. Date of Electronic Publication: 2018 Sep 27.
DOI: 10.23736/S0392-0488.18.06143-6
Abstrakt: The fixed-combination of Cal/BD aerosol foam is now entering the Italian market. This drug was developed with a technology that allows an enhanced penetration of the active ingredients into the skin. This enhanced penetration improves local bioavailability and, consequently, Cal/BD aerosol foam therapy is associated with improved clinical outcomes if compared with other products with the same components. The efficacy and safety of Cal/BD aerosol foam were confirmed both in clinical trials and in "field-practice" studies. This short review discusses current evidence on the Cal/BD aerosol foam combination; some preliminary data collected in the Italian clinical practice will be also presented.
Databáze: MEDLINE